
Johnson & Johnson’s Covid Vaccine 66% Effective
Johnson & Johnson's Covid-19 vaccine just emerging from Phase 3 clinical trials showed 66% efficacy in moderate to severe disease, and as much as to 85% in severe disease, the US healthcare group said in its first report on trial results.







































